Inhibrx Biosciences, Inc. ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced positive topline ...
SHELTON, CONNECTICUT / ACCESS Newswire / October 22, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer:NNVC) (the “Company”), announced that its clinical lead drug NV-387 has shown ...
Zacks Investment Research on MSN
Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock?
Eli Lilly and Company’s LLY stock has risen 9.5% in a month, mainly due to the recent recovery in the pharma sector. The drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback